GlassScriptPhysician profile
Kimberly A Thomas
NPI 1699580167
$997.26
in general payments reported to CMS, 2019-2025
24 companies · $997 in 2025
The $997 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.28 |
| Education | $124.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $215.41 | 2025 | |
| Incyte Corporation | $147.71 | 2025 | Jakafi, Zynyz, Monjuvi |
| Astellas Pharma US INC | $74.99 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $72.82 | 2025 | Enhertu |
| Daiichi Sankyo INC. | $62.11 | 2025 | Enhertu, Datroway |
| Pharmacosmos Therapeutics INC. | $52.74 | 2025 | Monoferric |
| Janssen Biotech, INC. | $50.13 | 2025 | Darzalex, Carvykti |
| Abbvie INC. | $47.93 | 2025 | |
| Tersera Therapeutics LLC | $20.66 | 2025 | Zoladex |
| Aveo Pharmaceuticals, INC. | $19.96 | 2025 | |
| Sobi, INC | $19.56 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.54 | 2025 | |
| Acrotech Biopharma INC. | $18.77 | 2025 | Ryzneuta |
| Gilead Sciences, INC. | $18.55 | 2025 | Trodelvy |
| Pharmaessentia USA Corporation | $17.95 | 2025 | Besremi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $17.87 | 2025 | |
| Jazz Pharmaceuticals INC. | $17.77 | 2025 | |
| Celgene Corporation | $17.72 | 2025 | Reblozyl |
| Spectrum Pharmaceuticals INC. | $17.70 | 2025 | Rolvedon |
| Genmab U.S., INC. | $16.96 | 2025 | Tivdak |
| Geron Corporation | $16.83 | 2025 | Rytelo |
| Helsinn Therapeutics (U.S.), INC. | $15.98 | 2025 | Akynzeo |
| Alnylam Pharmaceuticals INC. | $14.03 | 2025 | Givlaari |
| Pharmaand Gmbh | $3.57 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.